Boston Scientific Corp. (BSX)
$8.17
0.02 (+0.25%)
| CAPS Rating |
|
|---|---|
| Open | $8.22 |
| Previous Close | $8.15 |
| Daily Range | $8.08 - $8.24 |
| 52-Week Range | $6.08 - $11.77 |
| Market Cap | $12.34B |
| P/E Ratio | 9.19 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 13,580,452 |
| Average Daily Volume | 0 |
BSX
VS S&P 500 (SPY)
How do you think BSX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BSX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BSX News and Commentary
- What Bipartisan Health-Care Reform Means for Investors – The Motley Fool
- Medical-Devices Sector Could Face Tougher Regulatory Pathway – SmartMoney
- This Dumb Move Could Kill Your Retirement – The Motley Fool
- Now That's Some Expensive Risk Mitigation – The Motley Fool
- Boston Scientific to Pay J&J $1.73 Billion to Settle Suit – Fox Business
- 2nd UPDATE: Boston Scientific To Pay J&J $1.73 Billion In Settlement – SmartMoney
- UPDATE: Boston Scientific To Pay J&J $1.73 Billion In Settlement – SmartMoney
- MARKET SNAPSHOT: U.S. Stock Get Momentum From Manufacturing Data – SmartMoney
- MARKET SNAPSHOT: U.S. Stocks Climb To Kick Off February – SmartMoney
- Boston Scientific To Pay J&J $1.73 Billion To Settle Stent Patent Disputes – SmartMoney
- UPDATE 1-Boston Sci to pay J&J $1.73 bln in settlement – Reuters
- Humira or Not, Abbott's on a Roll – The Motley Fool
- UPDATE: St. Jude Posts 4Q Profit, Aims For US Improvements – SmartMoney
- UPDATE: Boston Scientific: Court Rules J&J Patents Invalid – SmartMoney
- Boston Scientific: Court Rules J&J Patents Invalid – SmartMoney
- 3 Drug Stocks With Low P/Es & Healthy Dividends – SmartMoney
- JPMorgan Challenge: Do You "Heart" This Company? – The Motley Fool
- Boston Scientific aims to grow beyond stents, ICDs – Reuters
- J.P. Morgan Challenge: Making Money Off Molars Edition – The Motley Fool
- Boston Scientific Wants To Spend On Growth, Not Big Studies – SmartMoney
RSS Headlines
Fool UK
